Support of Cerebrospinal Fluid Biomarker Study–ADNI


Cure Alzheimer’s Fund is part of a funding consortium supporting collaborative biomarker investigation of the elevation of tau and decreased concentrations of Amyloid beta 42 in the cerebrospinal fluid (CSF) as evidence of the presence of the Alzheimer’s disease pathology.

Funding to Date



Biomarkers/Diagnostics/Studies of Risk & Resilience, Foundational


John Q. Trojanowski, M.D., Ph.D.

Leslie M. Shaw, Ph.D.

Related Content: